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Abstract 47 
Background: Remote ischaemic conditioning (RIC) has been shown to reduce myocardial 48 
infarct size in animal models of myocardial infarction. Platelet thrombus formation is a 49 
critical determinant of outcome in ST-segment elevation myocardial infarction (STEMI). 50 
Whether the beneficial effects of RIC are related to thrombotic parameters is unclear.  51 
Methods and Results: In a pre-specified substudy of the Effect of Remote Ischaemic 52 
Conditioning on clinical outcomes in STEMI patients undergoing Primary Percutaneous 53 
Coronary Intervention (ERIC-PPCI) trial, we assessed the effect of RIC on thrombotic status. 54 
Patients presenting with STEMI were randomised to immediate RIC consisting of an 55 
automated autoRICTM cuff on the upper arm inflated to 200mmHg for 5 minutes and deflated 56 
for 5 minutes for 4 cycles (n=53) or sham (n=47). Venous blood was tested at presentation, 57 
discharge (48 h) and 6-8 weeks, to assess platelet reactivity, coagulation and endogenous 58 
fibrinolysis using the Global Thrombosis Test and thromboelastography (TEG). Baseline 59 
thrombotic status was similar in the 2 groups. At discharge, there was some evidence that the 60 
time to in vitro thrombotic occlusion under high shear stress was longer with RIC compared 61 
to sham (454±105s vs. 403±105s; mean difference 50.1s; 95% confidence interval [CI] 93.7-62 
6.4, P=0.025), but this was no longer apparent at 6-8 weeks. There was no difference in clot 63 
formation or endogenous fibrinolysis between the study arms at any time-point.  64 
Conclusion: RIC may reduce platelet reactivity in the first 48h post-STEMI. Further research 65 
is needed to delineate mechanisms through which RIC may reduce platelet reactivity, and 66 
whether it may improve outcomes in patients with persistent high on-treatment platelet 67 
reactivity.     68 
Word count: 259 words 69 
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Abbreviations 71 
ADP = adenosine diphosphate 72 
DAPT = dual antiplatelet medication 73 
GTT = Global Thrombosis Test 74 
IPC = ischaemic preconditioning 75 
IR = ischaemia-reperfusion 76 
IRI = ischaemia-reperfusion injury 77 
LT = lysis time 78 
OT = occlusion time 79 
PPCI = primary percutaneous coronary intervention 80 
RIC = remote ischaemic preconditioning 81 
STEMI = ST-segment elevation myocardial infarction 82 
TEG = thromboelastography 83 
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Introduction 85 
The cause of ST-segment elevation myocardial infarction (STEMI) is most commonly the 86 
disruption of a coronary atheromatous plaque, leading to local thrombosis, and culminating in 87 
arterial occlusion. The outcome of such a prothrombotic stimulus is determined by the 88 
magnitude of the thrombotic response, balanced against the effectiveness of the endogenous 89 
fibrinolytic enzymes in overcoming lasting vessel occlusion.1 Treatment of STEMI patients 90 
with primary percutaneous coronary intervention (PPCI) aims to rapidly restore coronary 91 
flow, improve myocardial salvage and reduce infarct size. However, reperfusion has also 92 
been associated with consequent downstream myocardial reperfusion injury, which may 93 
further compound the deleterious effects of the antecedent period of ischaemia.2–4 Measures 94 
to ameliorate the thrombotic response and reduce ischaemic-reperfusion injury (IRI) have 95 
been proposed to reduce infarct size.1,3–5 96 
Ischaemic preconditioning (IPC) refers to the ability of brief, cyclic periods of ischaemia and 97 
reperfusion (IR) to render the myocardium more resistant to a subsequent ischaemic insult. In 98 
animal models, IPC has been shown to reduce infarct size and to enhance recovery of 99 
contractile function of the myocardial region at risk.6 Remote ischaemic conditioning (RIC) 100 
involves the application of one or more brief cycles of IR to a “remote” organ (such as the 101 
arm or leg) and in animal models, has been shown to reduce infarct size and IRI.7–9 102 
Application of RIC in humans by repeated inflation and deflation of a blood pressure cuff on 103 
the upper arm has been shown to reduce the extent of perioperative myocardial injury in 104 
patients undergoing cardiac surgery in smaller studies,10 although it did not improve clinical 105 
outcomes in large studies.11,12 Compared to standard care, the use of RIC in patients 106 
undergoing PPCI has been associated with reduction in myocardial injury and increased 107 
myocardial salvage, without definitive reduction in infarct size or improvement in 108 
survival.13,14 109 
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The exact mechanism through which RIC potentially confers cardioprotection in STEMI is 110 
still not fully understood.15,16 Proposed mechanisms include generation of an endogenous 111 
substance such as adenosine, bradykinin or other factor, which activates a neural pathway; 112 
mediation by an endogenous substance generated in the remote organ which enters the blood 113 
stream to affect cardioprotection; or through a systemic protective response, suppressing 114 
inflammation and apoptosis.15,16 Additionally, IPC has been linked to favourable effects on 115 
thrombotic markers. In a canine model, IPC was accompanied by down-regulation of platelet-116 
fibrinogen binding and formation of neutrophil-platelet aggregates.17 In stable CAD, remote 117 
ischaemia was shown to induce protection against an exercise-related increase in platelet 118 
reactivity18 and reduced ADP-stimulated platelet aggregation. In patients undergoing 119 
radiofrequency ablation for atrial fibrillation, RIC reduced platelet activation and platelet 120 
reactivity.19 Since platelet reactivity, activation of coagulation and endogenous fibrinolytic 121 
pathways are important drivers and determinants of the outcome of myocardial infarction,20 122 
and may play a role in IRI,21 we hypothesised that the benefit of RIC in STEMI may be 123 
mediated through anti-thrombotic effects. The aim of this study was to determine whether 124 
RIC improves thrombotic status in patients with STEMI undergoing PPCI. 125 
 126 
  127 
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Methods 128 
Study design and population 129 
We undertook a substudy of the Effect of Remote Ischaemic Conditioning on clinical 130 
outcomes in ST-segment elevation myocardial infarction patients undergoing Primary 131 
Percutaneous Coronary Intervention (ERIC-PPCI) multicentre, randomised, single-blind, 132 
placebo-controlled clinical trial (ClinicalTrials.gov NCT02342522).22 Patients with chest pain 133 
and suspected ST-segment elevation on the electrocardiogram (ECG) were screened for 134 
possible inclusion. Patients were included if they were older than 18 years of age, had ST-135 
segment elevation on ECG, were eligible for PPCI and gave consent. Exclusion criteria were 136 
previous coronary artery bypass graft surgery, myocardial infarct within the previous 30 days, 137 
left bundle branch block on ECG, treatment with therapeutic hypothermia, conditions 138 
precluding use of remote ischaemic conditioning (paresis of upper limb or presence of an 139 
arteriovenous shunt), and life expectancy of less than 1 year due to a non-cardiac pathology. 140 
All patients recruited to ERIC-PPCI in a single centre at the Lister Hospital, East & North 141 
Hertfordshire NHS Trust, were included in the substudy. The study was approved by the 142 
National Research Ethics Service and was conducted in accordance with the principles of 143 
Good Clinical Practice and the trial conformed to the principles outlined in the Declaration of 144 
Helsinki. All patients provided initial verbal assent before randomisation, which was 145 
followed by written informed consent. 146 
 147 
Trial treatment protocol 148 
The trial protocol and main clinical results have been previously published.22,23 In brief, 149 
patients were randomised in a 1:1 ratio to active treatment with RIC or control treatment with 150 
sham RIC (Figure 1). Randomisation was performed via a secure website using random 151 
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permuted blocks. Patients randomised to the interventional arm received RIC protocol using 152 
the automated AutoRIC cuff device (CellAegis Devices, Toronto, ON, Canada), comprising 153 
of four alternating cycles of cuff inflation to 200 mm Hg for 5 min and deflation for 5 min. 154 
The control group received a sham simulated RIC. The PPCI procedure was performed 155 
according to standard clinical care and PPCI operators and patients were blinded to treatment 156 
allocation. Study team members collecting the data and assessing outcomes were masked to 157 
treatment allocation.  158 
All patients received 300 mg aspirin orally and 600 mg clopidogrel or 180 mg ticagrelor 159 
orally, and standard weight-adjusted heparin intravenously prior to PPCI. Dual antiplatelet 160 
therapy was continued in all patients throughout the substudy. 161 
 162 
Blood sampling technique 163 
Blood samples were taken at three time points: 1) baseline upon arrival to the cardiac 164 
catheterisation laboratory (day 0), prior to heparin or glycoprotein IIb/IIIa inhibitor 165 
administration and before PPCI, 2) at clinical stabilisation, just prior to hospital discharge, 166 
and 3) at 6-8 weeks follow-up. The first blood samples were taken from a 6-F radial or 167 
femoral sheath, after the administration of dual antiplatelet therapy (DAPT) but before 168 
treatment with unfractionated heparin. Prior to insertion, the sheaths were flushed with 169 
normal saline, avoiding the use of heparinised saline prior to the first blood draw. The second 170 
and subsequent blood samples were taken from an antecubital vein using an 18-G butterfly 171 
cannula, taking care to avoid prolonged tourniquet time. All samples were taken using a 2-172 
syringe technique, which involved using the first 5 ml blood for routine blood tests, and the 173 
subsequent sample for assessment of thrombotic status.  174 
 175 
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Assessment of global thrombotic status  176 
Global Thrombosis Test (GTT) 177 
The GTT (Thromboquest Ltd., London, UK) assesses both platelet reactivity (occlusion time, 178 
OT) and endogenous fibrinolysis (lysis time, LT) from a 4 ml native, non-anticoagulated 179 
blood sample. The instrument was positioned in the cardiac catheterisation laboratory. After 180 
the blood sample was obtained, it was introduced into the GTT cartridge within 15 seconds of 181 
withdrawal and the automated measurement begun. The principle of the GTT has been 182 
previously described in detail.24,25 The instrument assesses firstly the time taken to form an 183 
occlusive thrombus under high shear (occlusion time, OT; sec), a marker of platelet 184 
reactivity. Shorter OT represents enhanced platelet reactivity. The arrest of flow due to the 185 
formation of an occlusive platelet thrombus, is followed by a short stabilisation period, after 186 
which the instrument records the time required for spontaneous restart flow due to 187 
endogenous thrombolysis of the thrombus formed in the first phase (lysis time, LT; sec). 188 
Longer LT represent less effective endogenous fibrinolysis.  189 
Thromboelastography (TEG) 190 
Blood was also tested using the TEG thromboelastograph (TEG 5000 Hemostasis Analyser 191 
system, Haemonetics, UK). Two tests were carried out per patient in parallel; whole blood 192 
(without the addition of any modifiers) and whole blood plus kaolin (Haemonetics, Watford, 193 
UK). Whole blood testing was performed immediately after sampling, whereas whole blood 194 
plus kaolin was performed within 4 minutes of sampling. The TEG generates a characteristic 195 
curve of thrombus formation and lysis with several indices, and definition of these is shown 196 
in Table 1.26 197 
 198 
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Study end-points 199 
The endpoint of the substudy was thrombotic status as measured by GTT and TEG 200 
parameters, in the RIC compared to the sham arms, at discharge and at 6-8 weeks. The 201 
primary combined endpoint of the main study was cardiac death or hospitalisation for heart 202 
failure at 12 months and these results have been published.22 203 
Data collection and follow-up 204 
Patient case-notes were checked throughout the course of the index admission, to allow 205 
contemporaneous data collection. Patients were followed up at 6-8 weeks in person including 206 
final blood draw for thrombotic status assessment. 207 
 208 
Statistical analysis 209 
In this pilot, hypothesis-generating substudy, we aimed to compare thrombotic status within 210 
groups (between patients on admission and at discharge and follow-up) and between groups 211 
(between RIC and sham). For a main trial designed with 90% power and two-sided 5% 212 
significance, it is recommended that a pilot trial sample size of at least 20 per treatment arm 213 
is needed for estimated small (0.2) standardised effect size,27 which was speculated from 214 
earlier studies.25 Therefore, a study of 100 patients (50 per treatment arm) was felt to be of 215 
sufficient size to produce meaningful results. Data are presented as mean and standard 216 
deviation (when normally distributed) or median and inter-quartile range [IQR] (non-217 
normally distributed). Normality was tested using the Shapiro-Wilk test. Differences in 218 
thrombotic variables at differing time-points in the group as a whole were assessed using 219 
paired-t-tests and Mann-Whitney U test. Difference between RIC and sham groups at any 220 
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individual time-point were assessed using ANCOVA. Analyses were performed with Stata 221 
version 11.2 (StataCorp, College Station, TX, USA). 222 
 223 
 224 
Results 225 
 226 
Between February 2016 and March 2018, 100 patients with STEMI were enrolled into the 227 
substudy, and randomised to RIC (n=53) or sham RIC (n=47) (Supplementary Figure 1). The 228 
main ERIC-PPCI study results have already been published.22 Baseline clinical 229 
characteristics are shown in Table 2 and baseline haematological and biochemical profiles in 230 
Table 3. There were no patients with atrial fibrillation or patients taking oral anticoagulation 231 
included in this substudy. Angiographic, interventional and echocardiographic patient 232 
characteristics are shown in Table 4. The RIC and sham groups were well matched for all 233 
aforementioned characteristics. In particular, there was no significant difference in either 234 
peri-procedural or post-PPCI antithrombotic treatment allocation between the treatment arms. 235 
 236 
Global Thrombosis Test (GTT) results 237 
In the whole cohort (n=100), OT increased from baseline to hospital discharge (338±129s vs. 238 
430±107s, p<0.001) and further increased at 6-8 weeks (baseline vs. 6-8 weeks 338±129s vs. 239 
493±132s, p<0.001)(Figure 2A).   240 
Baseline OT was similar in the RIC and sham groups, with mean difference 19.65s (95% 241 
confidence interval [CI] 69.41-70.36) (Table 5, Figure 3). However, there was some evidence 242 
that OT at hospital discharge was prolonged in RIC group compared to sham (454±105s vs. 243 
403±105s; mean difference 50.1s; 95% CI 6.4-93.7, P = 0.025), but this was less apparent at 244 
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6-8 weeks follow-up (538±142s vs. 511±142s, mean difference 27.5s; 95%CI 102.5- 47.5, 245 
P=0.818) (Table 5, Figure 3).  246 
Distribution of LT at the prespecified time points is shown in Figure 2-B. There was no 247 
evidence for a difference in LT between the two study arms at any of the time points (Figure 248 
4 and Table 5). 249 
 250 
Thromboelastography (TEG) results 251 
There was no evidence for a difference in any of the TEG indices using whole blood with or 252 
without kaolin between the two study arms at any of the time points, either with respect to 253 
coagulation parameters or indices of clot lysis (Table 5).  254 
 255 
DISCUSSION 256 
 257 
In this small, hypothesis generating substudy, in the group as a whole, OT was higher at 258 
discharge compared to admission, presumably reflecting reduction in platelet reactivity, due 259 
to onset of action of DAPT. However, although baseline thrombotic status at presentation 260 
was similar in patients in both RIC and sham RIC groups, patients receiving RIC exhibited 261 
significantly longer OT, representative of reduced platelet reactivity, at the time of hospital 262 
discharge compared to patients treated with sham RIC. This is, to our knowledge, the first 263 
time that RIC has been linked to reduced occlusive thrombus formation under high-shear 264 
stress, in the setting of STEMI in humans.  265 
The encouraging results of this substudy contrast with the neutral results of the main CONDI-266 
2/ERIC-PPCI trial, in which no difference was seen between the RIC and the control groups 267 
with respect to the combined primary endpoint of cardiac death or hospitalisation for heart 268 
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failure at 12 months (HR 1.10; 95% CI 0.91–1.32; P = 0.32), demonstrating that RIC, applied 269 
as an adjunct to PPCI, did not improve clinical outcomes in STEMI patients. The discrepancy 270 
between the findings of our small substudy and the main trial may simply be due to the play 271 
of chance in a small sample. However, if these results are real, and RIC results in reduced 272 
platelet reactivity at 48h post-PPCI, it would not be surprising if this in fact had no effect on 273 
outcomes. The reduction in platelet reactivity at 48h may be too late to influence reperfusion 274 
and infarct size, or to favourably impact on any reperfusion injury following PPCI. This 275 
might indicate that earlier application of such RIC may have improved outcomes, although in 276 
the main CONDI-2/ERIC-PPCI trial, there were no differences in clinical outcomes whether 277 
RIC was performed in the ambulance or in hospital. Another consideration is that platelet 278 
reactivity is a strong determinant of ischaemic outcomes, in particular in the highest risk 279 
patients. Although acute stent thrombosis is likely multifactorial in aetiology, it has been 280 
been related in part to enhanced platelet reactivity, and so it is possible that a beneficial effect 281 
in reducing platelet reactivity could reduce the occurrence of acute stent thrombosis, although 282 
there was no signal for this in the main CONDI-2/ERIC-PPCI trial, where the occurrence of 283 
myocardial infarction at 30 days was similar in the RIC and sham arms. The CONDI-284 
2/ERIC-PPCI trial excluded many patients with anterior STEMI, since these often exhibit left 285 
bundle branch block, and patients with cardiogenic shock who were unable to give consent. 286 
Patients with cardiogenic shock are not only at very high cardiovascular risk with 30-50% 287 
risk of death or recurrent ischaemic events over the subsequent 30 days, but shock can also 288 
limit the effectiveness of orally-administered antithrombotic medications due to delayed drug 289 
administration, reduced gastrointestinal blood flow and motility, delayed gastric emptying 290 
and gastrointestinal absorption29- so these patients may have the most to gain from 291 
approaches that reduce platelet reactivity. Since the effect on platelet reactivity was no longer 292 
apparent at 6-8 weeks, this may explain the lack of effect on long term ischaemic outcomes. 293 
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Whilst current guidelines advocate use of the more potent P2Y12 inhibitors ticagrelor and 294 
prasugrel in patients with STEMI,30 this also comes at a greater price of bleeding. 295 
Clopidogrel continues to be used in a significant number of ACS patients in high income 296 
countries,31 and also for financial reasons in low income countries.32 Up to a third of ACS 297 
patients demonstrate inadequate platelet inhibition in response to clopidogrel.33 This is 298 
explained in part by polymorphisms in the gene encoding the hepatic enzyme CYP2C19, 299 
which transforms clopidogrel to its active metabolite, that can result in 5-12% variation in 300 
platelet inhibition.34 There is ethnic variation in the prevalence of the loss-of-function 301 
CYP2C19 618G>A*2 allele, affecting some 30% of Caucasians and 50% of East Asians.33 302 
Homozygotes for the CYP2C19*2 and less common CYP2C19*3 LoF alleles are poor 303 
metabolizers, and heterozygotes are intermediate metabolizers of clopidogrel, with high-on 304 
clopidogrel platelet reactivity and increased risk of adverse cardiovascular events, including 305 
AMI and stent thrombosis.35–37 The association of CYP2C19 genotype with increased 306 
cardiovascular risk appears greatest in those undergoing PCI, and the risk is greater in Asians 307 
than in whites.38 Enhancing platelet inhibition with RIC in patients who are receiving 308 
clopidogrel may be particularly advantageous in such patients. 309 
 310 
Possible mechanisms 311 
A possible mechanism underlying the beneficial effects of RIC is a direct effect on arterial 312 
thrombus formation. In humans, marked platelet activation has been demonstrated in patients 313 
presenting with acute coronary syndrome39,40 and platelets have an important role not only in 314 
epicardial coronary thrombosis, but also in the pathophysiology of IRI and IPC.41–43 315 
The relationship between RIC and platelet activation is less well explored in patients, with 316 
most knowledge derived from animal studies and healthy volunteers. In rats, RIC reduced 317 
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arterial thrombus formation and embolization under direct visualisation by microscopy 318 
following femoral arterial injury44 and in rodent hearts ex vivo, the extent of myocardial 319 
injury following IR injury is was directly related to the activation status of platelets, with 320 
reduced infarct size in mice treated with platelet-poor plasma.42 Platelet-derived 321 
microparticles may mediate RIC, since platelet microparticles isolated from rats receiving 322 
RIC reduced the extent of cerebral infarction when transfused into recipient rats.45 In dogs 323 
subjected to coronary IR injury, IPC attenuated platelet activation and aggregation17,46 and 324 
was abolished by pre-treatment with an adenosine antagonist, linking preconditioning with 325 
platelet thrombus formation.46 326 
Studies in healthy individuals support the concept that RIC inhibits platelet activation. In 327 
healthy volunteers, the increase in the circulating concentration of platelet–monocyte 328 
aggregates associated with acute IR injury was abolished by RIC.47 In normal volunteers, 329 
RIC of forearm reduced expression of neutrophil CD11b and platelet–neutrophil 330 
complexes.48 Studies in patients with cardiovascular disease are limited. In patients with 331 
stable coronary disease, RIC attenuated platelet activation in response to adenosine 332 
diphosphate (ADP) and exercise18 and in patients with claudication, warm-up (a phenomenon 333 
akin to IPC) prior to exercise attenuated the exercise-induced increase in platelet–neutrophil 334 
and platelet–leukocyte activation.49 In patients undergoing ablation for atrial fibrillation, 335 
RIPC reduced platelet activation in response to ADP, including the formation of monocyte-336 
platelet aggregates.19 Other studies found that intermittent upper arm IR reduced platelet 337 
activation and aggregation in response to ADP in patients with stable angina undergoing 338 
angiography or elective angioplasty.50  339 
If the effect of RIC is marked in animals, in healthy volunteers and patients with stable 340 
cardiovascular disease, why not in patients with myocardial infarction? A key difference 341 
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between these cohorts, is that patients with myocardial infarction receive DAPT comprising 342 
of aspirin and a P2Y12 inhibitor as part of standard of care.30 In healthy male volunteers, pre-343 
treatment with aspirin did not influence the effect of RIC on platelet aggregation and 344 
turnover.51 However, preclinical studies indicate that P2Y12 inhibitors may have direct 345 
cardioprotective effects independent of inhibition of platelet-mediated thrombosis. In animal 346 
studies, P2Y12 inhibitors were shown to reduce infarct size in rabbits, rats and nonhuman 347 
primates.52–55 Furthermore, although P2Y12 inhibitors proposed to act on cardiomyocytes and 348 
upregulate cardioprotective signaling in a manner analogous to IPC,56 these drugs failed to 349 
reduce infarct size in buffer-perfused hearts, indicating that blood, and specifically platelets, 350 
are required to confer cardioprotection.54,57 There are however some data supporting the 351 
concept that clopidogrel may reduce infarct size through the attenuation of reperfusion injury 352 
and the protective effect appeared to add to the benefit afforded by ischaemic 353 
postconditioning .55,58 It is therefore possible that the benefits of RIC in STEMI may be 354 
attenuated by P2Y12 inhibitor treatment59,60 and one can postulate that RIC may confer greater 355 
cardioprotection in patients with persistent high on-treatment platelet reactivity. 356 
The lack of effect of RIC on markers of coagulation in TEG are not altogether surprising. 357 
Although RIC in patients with subarachnoid haemorrhage appeared to prolong the 358 
prothrombin time and international normalised ratio after at least 4 sessions, values remained 359 
within normal range.56 360 
We did not observe an effect of RIC on in vitro endogenous fibrinolysis. In patients with 361 
STEMI, pre-infarction angina (thought to provide IPC) was associated with a significant 362 
reduction in the time to achieve thrombolysis-induced reperfusion.61 This was confirmed in 363 
animal studies where recombinant tissue-type plasminogen activator -induced thrombolysis 364 
was significantly shortened in animals that received brief antecedent IPC.62 Our findings of a 365 
lack of effect of RIC on fibrinolysis is supported by a study in healthy subjects, where IRI 366 
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was shown to induce  fibrinolytic dysfunction evidenced by reduced tissue plasminogen 367 
activator release that could not be prevented by local IPC or RIC.63 However, global tests of 368 
fibrinolysis, such as performed here, and which give better assessment of global fibrinolytic 369 
status than factorial measures such as tissue-plasminogen activator and plasminogen activator 370 
inhibitor-1 levels,20 have not been studies in either animal or human studies. 371 
 372 
Limitations 373 
An important limitation of our study is the small sample size. Any observed differences over 374 
time or between groups could be due to the play of chance. Furthermore, the exact timeline of 375 
effect of RIC on thrombotic status is difficult to conclude, due to the paucity of sampling 376 
times. Although a weakness of our study is that mechanistically, we cannot elucidate the 377 
cause of the reduced platelet reactivity in patients with RIC, a strength of our work is that we 378 
used tests of global thrombotic status, assessing whole blood and in particular, non-379 
anticoagulated blood at high-shear, akin to that in a stenosed coronary vessel, making the 380 
findings in vitro much more physiologically-relevant, than tests on anticoagulated blood at 381 
low shear. With respect to the timing of RIC, a recent meta-analysis showed that RIC 382 
protocols that are conducted predominantly before the initiation of reperfusion as opposed to 383 
protocols with frequent RIC cycles conducted after reperfusion, conferred more 384 
cardioprotection.64 Although in the ERIC-PPCI study, the start of RIC was before 385 
reperfusion, the whole protocol was not always complete before the reperfusion occurred. 386 
Upstream start of RIC earlier in the pathway may have improved the outcomes. 387 
 388 
Conclusions 389 
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Compared to sham treatment, there is a suggestion that RIC may exert a favourable effect on 390 
global thrombotic status in patients with STEMI undergoing PPCI, likely through a 391 
favourable effect on platelet reactivity. Further research is needed to delineate mechanisms 392 
through which RIC may attenuate thrombus formation at high shear stress, and to identify 393 
patients who may benefit most from this approach.    394 
  395 
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Figure legends 724 
Figure 1. ERIC-PPCI study flowchart 725 
Flowchart in black represents the ERIC-PPCI main study, whereas in blue represents the 726 
thrombosis substudy. Blood samples were taken at three time points, 1) baseline upon arrival 727 
to the catheterisation laboratory and at randomisation 2) at clinical stabilisation, just prior to 728 
hospital discharge, and 3) at 6-8 weeks follow-up. 729 
PIS: patient information sheet, SAEs: serious adverse events, NSAEs: non-serious adverse 730 
events 731 
 732 
Figure 2. Distribution of OT and LT at the pre-specified time points  733 
OT= occlusion time, LT= lysis time. *P<0.01 compared to baseline. OT at baseline vs. 734 
discharge (paired t-test: mean difference 92s, [95%CI 66.61-117.57], p<0.001). OT at 735 
baseline vs. 30 days (Mann-Whitney U test: mean difference 193s, [95%CI 158.29-229.61], 736 
p<0.001). 737 
 738 
Figure 3. Distribution of OT at the pre-specified time points between the study arms 739 
Occlusion time (OT) was significantly prolonged at hospital discharge in RIC group 740 
compared to sham RIC group. * Comparison between RIC and sham, P <0.05. † difference 741 
within group compared to baseline P<0.001. Comparison made using ANCOVA. 742 
 743 
Figure 4. Distribution of LT at the pre-specified time points between the study arms 744 
There was no significant difference in lysis time (LT) between the two study arms at any time 745 
point. Comparison made using ANCOVA. 746 
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Table 1. TEG indices and definitions 760 
Reaction Time (R) [min] Measures the time from the start of a sample run until the first 
significant level of detectable clot formation. R is shortened by 
hypercoagulable conditions 
Kinetics (K) [min] Measures the time from R until a fixed level of clot strength is 
reached. K is shortened by hypercoagulable conditions. When MA 
<20 mm, K is undefined  
Angle [degrees] Represents the rate of clot formation and reflects fibrinogen activity. 
Angle relates to K, since both are a function of the rate of clot 
formation. Angle is larger by hypercoagulable conditions  
Maximum Amplitude (MA) [mm] Represents whole clot strength and reflects many aspects of clot 
formation including platelet number and function as well as the 
fibrin contribution to clot strength. MA is larger by hypercoagulable 
conditions   
LY30 [%] Represents the percentage of clot which has lysed after 30 minutes 
of MA 
LY60 [%] Represents the percentage of clot which has lysed after 60 minutes 
of MA 
Time to Maximum Amplitude (TMA) 
[min] 
Measures the time to form maximum clot strength 
  761 
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Table 2. Baseline Patient Characteristics 762 
 
Whole Group  
(n=100)  
Sham RIC 
(n=47)  
RIC 
(n=53)  
P Value  
Age, yrs  65.2±13.6 65.1±13.1 65.4±14.1 0.903 
Male 79 (79.0) 37 (78.7) 42 (79.2) 1.000 
Caucasian 93 (93.0) 46 (97.9) 47 (88.7) 0.117 
BMI 26.7±4.2 26.9±4.8 26.6±3.6 0.673 
 TIMI score 3.1±2.4 2.9±2.3 3.3±2.5 0.467 
Diabetes mellitus  20 (20.0) 7 (14.9) 13 (24.5) 0.317 
Active smoker  27 (27.0) 15 (31.9) 12 (22.6) 0.369 
Hypertension 44 (44.0) 20 (42.6) 24 (45.3) 0.842  
Family history of premature IHD  26 (26.0) 13 (27.7) 13 (24.5) 0.820  
Prior MI 9 (9.0) 3 (6.4) 6 (11.3) 0.495 
Prior PCI 8 (8.0) 3 (6.4) 5 (9.4) 0.719 
Renal insufficiency 4 (4.0) 2 (4.3) 2 (3.8) 1.000 
PVD 3 (3.0) 3 (6.4) 0 0.100 
Prior CVA 4 (4.0) 1 (2.1) 3 (5.7) 0.620 
Prior statin use 26 (26.0) 14 (29.8) 12 (22.6) 0.496 
Prior aspirin use  16 (16.0) 5 (10.6) 11 (20.8) 0.186 
Prior P2Y12 inhibitor use 1 (1.0) 0 1 (1.9) 1.000 
Initial P2Y12 inhibitor loading agent  
 
 
  
          Clopidogrel 76 (76.0) 37 (78.7) 39 (73.6) 0.642 
          Ticagrelor 20 (20.0) 8 (17.0)  12 (22.6) 0.618  
          Cangrelor 4 (4.0) 2 (4.3) 2 (3.8) 1.000 
  Morphine prior to blood sample 59 (59.0) 26 (55.3) 33 (62.3) 0.544 
  Time from P2Y12 inhibitor loading to first 
blood sample (min) 
46.9±21.9 46.9±19.1 46.9±24.2 0.979 
Medications prior to hospital discharge 
 
 
  
Aspirin  94 (94.0) 45 (95.7) 49 (92.5) 1.000 
Clopidogrel 12 (12.0) 7 (14.9) 5 (9.4) 0.540 
Ticagrelor  82 (82.0) 38 (80.9) 44 (83.0) 0.800 
Beta-blocker  91 (91.0) 44 (93.6) 47 (88.7) 1.000 
ACE inhibitor  93 (93.0) 45 (95.7) 48 (90.6) 1.000  
Calcium antagonist 6 (6.0) 1 (2.1) 5 (9.4) 0.206 
Statin 92 (92.0) 45 (95.7) 47 (88.7) 0.496 
Nitrate  2 (2.0) 0 2 (3.8) 0.497 
Insulin 3 (3.0) 2 (4.3) 1 (1.9) 0.599 
 763 
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Values are mean ± standard deviation or n (%). Renal insufficiency was defined as creatinine levels >177 μmol/L. 764 
Prior statin, aspirin or P2Y12 inhibitor use defined as regular statin, aspirin or P2Y12 inhibitor use before 765 
hospitalisation. Family history of premature IHD was defined as a diagnosis of IHD in a first-degree relative under 766 
the age of 60. 767 
ACE: angiotensin-converting enzyme, BMI: body mass index, CVA: cerebrovascular accident, IHD: ischaemic 768 
heart disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, PVD: peripheral vascular 769 
disease, TIMI: Thrombolysis in Myocardial Infarction.  770 
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Table 3. Haematological and biochemical profiles 771 
 Whole Group  
(n=100)  
Sham RIC 
(n=47)  
RIC 
(n=53)  
P Value  
Haemoglobin (g/L) 138±19 136±19 139±19 0.400 
Haematocrit (%) 41±6 40±6 41±5 0.516 
Neutrophil count (x109/L) 8.6±2.9 8.6±2.8 8.6±3.1 0.938 
Platelet count (x109/L) 259±77 258±78 260±77 0.923 
Serum albumin (g/L) * 43±3.7 42±3.8 43±3.7 0.243 
Sodium (mmol/L) 138±3 138±2 138±3 0.789 
Creatinine (µmol/L)   91±37 94±49 89±23 0.513 
Peak troponin T (ng/L) * 2223 [1072-3796] 2014 [993-3606] 2301 [1074-3945] 0.474 
Fibrinogen (g/L) 4.6±1.3 4.6±1.1 4.7±1.5 0.605 
PT (sec) 11.8±1.1 11.8±1.0 11.9±1.2 0.728 
aPTT (sec) 28.1±3.6 27.5±3.4 28.6±3.7 0.175 
Total cholesterol (mmol/L) 5.1±1.2 4.9±1.2 5.3±1.1 0.121 
LDL cholesterol (mmol/L) 2.9±0.8 2.9±0.9 2.9±0.7 0.867 
Hs C-reactive protein (mg/l) * 3 [1-8] 3 [2-8] 2 [1-8] 0.273 
 772 
Values are mean ± standard deviation, except * where values are median [IQR]. aPTT: activated partial 773 
thromboplastin time; LDL: low-density lipoprotein; PT: prothrombin time. All values measured at presentation, 774 
except peak troponin T. 775 
Normal values: haemoglobin 130-180 g/L (males) and 115-165 g/L (females); haematocrit 40-52% (males) and 776 
36-47% (females); neutrophil count 2-7.5 x109/L; platelet count 150-400 x109/L; serum albumin 34-54 g/L; serum 777 
sodium 135-145 mmol/L, creatinine 60-110 μmol/L (males) and 45-90 μmol/L (females); troponin T <14 ng/L 778 
(Elecsys high-sensitivity assay, Roche Diagnostics); fibrinogen 2–4 g/L; PT 11-13.5 seconds; aPTT 25-35 779 
seconds; total cholesterol ≤4.0 mmol/L; LDL cholesterol ≤2.0 mmol/L; high sensitivity C-reactive protein 0–3 780 
mg/l. 781 
  782 
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Table 4. Angiographic, Interventional and Echocardiographic Patient Characteristics 783 
 
Whole Group  
(n=100)  
Sham RIC 
(n=47)  
RIC 
(n=53)  
P Value  
Complete (>70%) ST-segment resolution on 
ECG pre-PPCI 
9 (9.0) 5 (10.6) 4 (7.5) 0.731 
Systolic blood pressure (mmHg) on arrival * 130±24 133±26 128±23 0.338 
Diastolic blood pressure (mmHg) on arrival * 78±16 80±16 76±15 0.275 
Heart rate (bpm) on arrival * 79±18 78±18 80±19 0.752 
Killip classification score >2 4 (4.0) 2 (4.3) 2 (3.8) 1.000 
Radial access 93 (93.0) 42 (89.4) 51 (96.2) 0.249 
1-vessel disease 54 (54.0) 23 (48.9) 31 (58.5) 0.422 
2-vessel disease 31 (31.0) 17 (36.2) 14 (26.4) 0.387 
3-vessel disease 15 (15.0) 7 (14.9)  8 (15.1) 1.000  
Culprit vessel LAD 44 (44.0) 16 (34.0) 27 (50.9) 0.107 
GPI (Tirofiban) use 32 (32.0) 16 (34.0) 16 (30.2) 0.830 
Thrombus aspiration 7 (7.0) 3 (6.4) 4 (7.5) 1.000 
DES implantation  95 (95.0) 43 (91.5) 52 (98.1) 0.184 
 Stent diameter <3 mm 31 (31.0) 16 (34.0) 15 (28.3) 0.388  
 TIMI 2/3 angiographic flow pre-PPCI 23 (23.0) 10 (21.3) 13 (24.5) 0.813 
TIMI 2/3 angiographic flow post-PPCI 99 (99.0) 47 (100) 52 (98.1) 1.000 
Myocardial blush grade 2/3 post-PPCI 95 (95.0) 46 (97.9) 49 (92.5) 1.000 
Door to first device time, min  29 [23-36] 29 [21-33]  30 [24-53] 0.179 
Call to first device time, min 101 [76-134] 98 [76-131] 103 [75-136] 0.882 
Pain to first device time, min 162 [118-263] 170 [119-276] 155 [117-235] 0.519 
Left ventricular function  
 
 
  
             Normal (EF ≥55%) 34 (34.0) 16 (34.0) 18 (33.9) 1.000 
             Mildly impaired (EF 45–54%) 36 (36.0) 16 (34.0) 20 (37.8) 0.835 
             Moderately impaired (EF 36–44%) 23 (23.0) 13 (27.7) 10 (18.9) 0.346 
             Severely impaired (EF ≤35%) 7 (7.0)  2 (4.3) 5 (9.4) 0.442 
  784 
Values are median [IQR] or n (%), except * where values are mean ± standard deviation. Left ventricular function 785 
was assessed by echocardiography prior to hospital discharge. 786 
DES: drug eluting stent, EF: ejection fraction, GPI: glycoprotein IIb/IIIa inhibitor, LAD: left anterior descending 787 
coronary artery, MI: myocardial infarction, PPCI: primary percutaneous coronary intervention, TIMI: 788 
Thrombolysis in Myocardial Infarction. 789 
Door to first device time was the time interval between the arrival of a patient at the hospital and the time of first 790 
intracoronary device use (defined as time of first balloon or stent inflation; or use of thrombectomy or angioplasty 791 
wire if these re-established flow). Call to device time was the time interval between the first call for help and first 792 
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device time. Pain to device time was the time interval between the onset of symptoms and the first intracoronary 793 
device use.  794 
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Table 5. Tests of thrombotic status 795 
 Whole Group  
(n=100)  
Sham RIC 
(n=47)  
RIC 
(n=53)  
P value  
Global Thrombosis Test (GTT)     
Baseline     
OT [sec] * 337±129 329±98 349±151 0.444 
LT [sec] 1660[1348-2255] 1574[1323-2284] 1670[1426-2146] 0.777 
At discharge     
OT [sec] * 430±107 403±105 454±105 0.025 
LT [sec] 1626[1328-2002] 1646[1406-2123] 1571[1284-1924] 0.241 
At 6-8 weeks     
OT [sec] * 493±132 471±132 512±130 0.144 
LT [sec] 1752[1387-2042] 1799[1451-2199] 1675[1296-2026] 0.227 
 
Thromboelastography (TEG)     
Baseline (native blood sample)     
Reaction Time (R) [min] 8.2[5.9-9.5] 8.2[5.9-9.6] 8.2[6.1-9.3] 0.841 
Kinetics (K) [min] 2.5[1.9-3.8] 2.2[1.8-3.4] 2.7[2.1-3.9] 0.124 
Angle [degrees] 56[45-64] 59[47-66] 53[39-62] 0.204 
Maximum Amplitude (MA) 
[mm] 
73[67-78] 72[69-78] 73[66-78] 0.889 
LY30 [%] 0.2[0-1.6] 0.7[0-3.5] 0.1[0-1.1] 0.099 
LY60 [%] 2.8[0.9-5.1] 3.5[1.2-7.2] 2.5[0.6-4.5] 0.279 
Time to Maximum Amplitude 
(TMA) [min] 
28.2[24.2-34.8] 26.2[23.4-32.9] 30.5[24.8-36.9] 0.242 
At discharge (native blood 
sample) 
    
Reaction Time (R) [min] 9.1[6.3-11.8] 10.6[6.3-11.8] 8.9[6.5-11.4] 0.865 
Kinetics (K) [min] 3.2[1.9-4.0] 3.5[1.9-3.9] 2.7[1.9-4.4] 0.864 
Angle [degrees] 53[46-65] 52[49-65] 58[41-64] 0.884 
Maximum Amplitude (MA) 
[mm] 
73[68-77] 73[69-77] 72[66-79] 0.990 
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LY30 [%] 0.8[0-4.7] 0.6[0.1-8.0] 1.1[0-3.9] 0.741 
LY60 [%] 3.5[1.2-9.7] 3.5[1.9-13.4] 3.7[1.2-9.5] 0.576 
Time to Maximum Amplitude 
(TMA) [min] 
30.6[22.2-33.6] 31.6[22.2-34.3] 27.0[22.2-32.1] 0.444 
At 6-8 weeks (native blood 
sample) 
    
Reaction Time (R) [min] 9.8[7.6-12.3] 9.7[8.0-12.3] 10.0[7.2-12.3] 0.882 
Kinetics (K) [min] 2.6[1.9-3.6] 2.8[1.9-3.5] 2.6[1.9-3.8] 0.974 
Angle [degrees] 58[49-65] 58[49-65] 61[49-64] 0.691 
Maximum Amplitude (MA) 
[mm] 
75[71-79] 76[69-79] 74[72-79] 0.817 
LY30 [%] 1.0[0.1-2.2] 1.2[0.1-2.1] 0.6[0.1-2.9] 0.855 
LY60 [%] 4.0[1.6-6.1] 4.0[1.8-6.1] 3.3[1.6-6.3] 0.585 
Time to Maximum Amplitude 
(TMA) [min] 
29.1[22.1-34.8] 27.0[20.6-33.7] 29.7[24.9-35.8] 0.260 
Baseline (Kaolin added)     
Reaction Time (R) [min] 5.1[3.2-5.9] 5.2[3.2-6.1] 5.0[3.5-5.9] 0.750 
Kinetics (K) [min] 1.2[1.1-1.4] 1.2[1.0-1.6] 1.2[1.1-1.4] 0.873 
Angle [degrees] 72[67-74] 71[67-75] 72[69-74] 0.811 
Maximum Amplitude (MA) 
[mm] 
76[72-81] 76[71-81] 76[74-79] 0.812 
LY30 [%] 1.1[0.2-4.3] 1.2[0-3.7] 1.0[0.3-5.4] 0.404 
LY60 [%] 4.5[2.0-8.1] 3.6[1.5-7.7] 5.4[2.3-8.2] 0.439 
Time to Maximum Amplitude 
(TMA) [min] 
20.8[17.7-23.8] 21.5[18.4-24.4] 19.6[16.9-23.8] 0.300 
At discharge (Kaolin added)     
Reaction Time (R) [min] 5.3[3.6-7.2] 5.9[3.8-7.2] 5.2[3.6-7.3] 0.919 
Kinetics (K) [min] 1.3[1.1-1.5] 1.3[1.1-1.5] 1.2[1.2-1.5] 0.859 
Angle [degrees] 72[67-75] 71[68-75] 72[67-74] 0.841 
Maximum Amplitude (MA) 
[mm] 
78[74-81] 76[75-80] 78[74-82] 0.606 
LY30 [%] 2.1[0.7-4.9] 1.8[0.6-4.8] 3.1[0.9-5.2] 0.624 
LY60 [%] 5.9[3.3-10.5] 5.1[3.2-9.5] 7.3[4.2-12.0] 0.473 
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Time to Maximum Amplitude 
(TMA) [min] 
20.7[17.9-23.4] 21.1[17.8-23.4] 20.2[18.4-23.2] 0.753 
At 6-8 weeks (Kaolin added)      
Reaction Time (R) [min] 5.7[3.9-7.3] 5.0[3.3-7.3] 6.6[4.3-7.3] 0.706 
Kinetics (K) [min] 1.4[1.1-1.7] 1.4[1.0-1.6] 1.4[1.2-1.8] 0.490 
Angle [degrees] 71[66-74] 71[69-75] 71[66-74] 0.544 
Maximum Amplitude (MA) 
[mm] 
78[75-82] 78[77-82] 77[74-82] 0.530 
LY30 [%] 2.0[0.5-3.8] 2.1[0.1-3.1] 2.0[0.5-4.4] 0.367 
LY60 [%] 5.0[2.4-7.5] 5.3[2.1-7.4] 3.7[2.5-7.5] 0.786 
Time to Maximum Amplitude 
(TMA) [min] 
21.0[17.4-25.8] 21.0[17.9-23.7] 20.7[17.4-25.9] 0.858 
 796 
Values are median [IQR] except * where are mean ± standard deviation.  797 
LT: lysis time, OT: occlusion time. For explanation of abbreviation of TEG indices, see 798 
Table 2. 799 
 800 
